Summary: Vigil Neuroscience Pharmaceutical Phase 1 Alzheimer's Trial

Vigil Neuroscience is currently conducting a Phase 1 Alzheimer's trial, and our goal is to propose a collaboration with the company to fund a test app. In exchange for funding, we would have access to data from patients who are not currently using Vigil Neuroscience's drug for Alzheimer's. This data could provide valuable insights into the natural progression of the disease and help in the development of more effective treatments.

Proposal for Funding a Test App for Non-Drug Users Suffering from Dementia

We have developed an innovative test app called DementiaCare, designed to collect and analyze data from dementia patients who are not currently using pharmaceutical products. This app monitors cognitive function, daily activities, and overall health status through cognitive tests, surveys, and health tracking features. By funding the development and implementation of DementiaCare, Vigil Neuroscience would gain exclusive access to this valuable data for a period of five years.

Benefits of Collaboration

Collaborating with Vigil Neuroscience on this project would provide several benefits:

  1. Unique Data Insights: The data collected from patients not using Vigil Neuroscience's drug can offer valuable insights into the natural progression of Alzheimer's disease. This information can help identify patterns and trends that may not be visible in patients using medication, leading to new treatment strategies.
  2. Enhanced Research Scope: By including patients not using the drug, the research scope would be broadened, providing a comprehensive understanding of Alzheimer's disease. This can contribute to the development of more effective treatments and improve patient care.
  3. Corporate Image Enhancement: This collaboration would demonstrate Vigil Neuroscience's commitment to comprehensive Alzheimer's research and patient care. It would showcase the company's dedication to understanding and combating the disease in all its forms, enhancing its corporate image.

Financial Commitment

The estimated cost for developing and implementing DementiaCare is approximately $500,000. This includes app development, data analysis, and user support. In return for funding, Vigil Neuroscience would have exclusive access to all data collected by the app for a period of five years.

Conclusion

We believe that this proposal offers a unique opportunity for Vigil Neuroscience to expand its research scope and contribute to the global fight against Alzheimer's disease. The collaboration would provide access to valuable data from patients not using the drug, offering insights into the natural progression of the disease and the effectiveness of non-pharmaceutical interventions. We look forward to discussing this opportunity further and are open to any suggestions or modifications you may have.

Thank you for considering our proposal.

Best regards,

Skyler Seegmiller, CEO

Walnut.ai